BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for aficamten.
BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for aficamten.
What's Your Reaction?
